<?xml version="1.0" encoding="utf-8"?><soap:Envelope xmlns:soap="http://www.w3.org/2003/05/soap-envelope" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><soap:Body><Protocol_or_StudyResponse xmlns="http://perdy.fhcrc.org/edrn_ws/ws_newcompass.asmx"><Protocol_or_StudyResult>&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;24&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;NYU Lung Cancer Biomarker Center&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;27&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Screen Detection of Mismatch Repair Deficient Colorectal Neoplasias Using a Stool Based DNA Analysis&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;28&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Detection Research Network Registry for Hereditary Cancer&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;36&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Preliminary Clinical Characterization of Serum Biomarkers for Colorectal Neoplasms&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;1. Men 35 or older
2. Men w/o prior history of prostate cancer if no increased risk for developing prostate cancer
3. Recommended 50 years of age, if no increased risk for developing prostate cancer
4. Recommended 40 years of age if they are either African-American or have a positive family history of prostate cancer (1st or 2nd degree relative), if increase risk of developing prostate cancer
5. Willing to allow samples to be collected and entered into SABOR Biorepository
6. Able to provide informed consent&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;52&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR)&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The Biomarker Development Laboratory is focused on the &amp;#060;br&amp;#062;application of a proteomic approach for the development&amp;#060;br&amp;#062; of cancer biomarkers.  The laboratory will apply &amp;#060;br&amp;#062;technologies for protein analysis to the detection and &amp;#060;br&amp;#062;identification of proteins secreted by tumor cells and &amp;#060;br&amp;#062;protein antigens that induce a humoral response in tumor&amp;#060;br&amp;#062;s.  The initial targeted tumor types for the identification&amp;#060;br&amp;#062; of potential biomarker proteins are:  Colon, esophagus,&amp;#060;br&amp;#062; ovary, lung, breast and liver.  The proposed studies will&amp;#060;br&amp;#062; make heavy utilization of two-dimensional (2-D) protein&amp;#060;br&amp;#062; analysis, of protein identification technologies and of &amp;#060;br&amp;#062;database capabilities that have been developed by the &amp;#060;br&amp;#062;applicant group.  The objectives of this research are &amp;#060;br&amp;#062;to 1.  Identify tumor antigens that induce a humoral &amp;#060;br&amp;#062;response; 2.  Identify tumor secreted proteins and develop&amp;#060;br&amp;#062;a database; 3.  Preliminarily validate the potential utility&amp;#060;br&amp;#062;of markers for early cancer detection.  Sixty ml of blood&amp;#060;br&amp;#062;will be obtained from healthy normals, and from small &amp;#060;br&amp;#062;cell lung cancer, hepatoma, esophageal, and breast cancer&amp;#060;br&amp;#062;patients, and from ovarian, colon, and non-small cell lung&amp;#060;br&amp;#062;cancer patients prior to surgical resection and six to&amp;#060;br&amp;#062;ten weeks after resection.  Demographic data, sera and &amp;#060;br&amp;#062;DNA will be used in 2-D protein analysis to identify new&amp;#060;br&amp;#062;or altered proteins.  The initial validation will be the &amp;#060;br&amp;#062;assay of the presence or absence of a given protein in a&amp;#060;br&amp;#062;large sample cohort from the samples collected from these&amp;#060;br&amp;#062;patients.  There is no specified age range, although the &amp;#060;br&amp;#062;diseases under study do not occur in children.  No subjects&amp;#060;br&amp;#062;will be excluded on the basis of race or gender.  Women&amp;#060;br&amp;#062;of child bearing age will be studied.  Linkable demographic&amp;#060;br&amp;#062;data will be held separately from the bar-coded serum or&amp;#060;br&amp;#062;DNA samples.  Serum and DNA sample will be identifiable&amp;#060;br&amp;#062;only by subject identification number.  Full written &amp;#060;br&amp;#062;informed consent will be obtained from patients.&lt;/value&gt;!!&lt;Identifier&gt;53&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomics Biomarker Development Laboratory&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;54&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of the Mutagen Sensitivity and Chromosomal Hotspot Assays&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;55&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detection of Serum Markers of Breast Cancer by SELDI&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;56&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Detection of Urinary Bladder Cancer&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Major strides in the early detection, staging, monitoring, and risk stratification of men with prostate cancer have been realized over the last few decades.  We have recently witnessed a reduction in the death rate for prostate cancer, stage migration with increased numbers of men with local/regional disease, and a greater understanding of the natural history of progression following recurrence.  These advances, while not solely dependant on biomarkers, can be attributed to the discovery of Prostate Specific Antigen (PSA) in the late 1970&amp;#39;s.  In the wake of these discoveries, we still continue to unnecessarily biopsy men at risk for having prostate cancer to identify the 1:4 with the disease, understage men with presumed local disease, continue to lack an accurate method for staging which can direct treatment options for the individual patient and continue to poorly understand the tumor biology and kinetics of disease progression.  Clearly, discovery of a new tumor marker and validation/clinical investigation of the markers are mandatory to advance our knowledge and direct the care of men with prostate cancer.  With this research, we intend to evaluate the clinical, diagnostic, and prognostic accuracy of new and existing biomarkers on a prospective serum bank collected from men either participating in early detection programs or engaging in pre or post treatment situations.  By increasing our clinical research and specimen collections we hope to further advance the staging and direction for treatment in men with prostate cancer.

This study approaches patients scheduled for a prostate biopsy, patients visiting the Urology Outpatient Clinic with PSA elevation, patients scheduled for radical prostatectomy, prostate cancer patients with scheduled appointments in Radiation Oncology and men participating in early prostate cancer detection screenings. 

Subjects will be excluded from the study if:
1)  Subjects have any mental impairment that would hinder the ability to provide informed consent.
2) The subject has undergone a radical prostatectomy and is visiting the urology clinic for a follow up appointment.  We can not evaluate the protein profiles in the serum/urine for this group of patients because of prostate removal.  
3)  Subjects have had previous chemotherapy treatment.  Such treatments often induce oxidative damage that could affect protein expression. Therefore, such patients are excluded as their exposure histories may be confounded with respect to exposures relevant to prostate cancer.
4) The patient has had previous prostate surgery. These procedures will affect protein expression.
5)  Subjects have had previous cancer other than non-melanoma skin cancer.  Systemic oxidative DNA damage is suspected as a potential etiologic factor in a number of other cancers.  Therefore, such patients are excluded as their exposure histories maybe confounded with respect to exposures relevant to prostate cancer.

Upon receiving consent, urine and blood specimens are collected from the subjects.  The urine and blood are then processed and stored in our freezer bank.  This study represents little to no risk to the patient. Risks include mild pain and bruising which may result from the needle stick. There is a very small chance of infection.  There is also a very small chance that the patient may feel faint or pass out from the needle stick.  These are the usual risks associated with phlebotomy. Collection of the urine introduces no increased risk to the patient. Adverse experiences that are both serious and unexpected will be immediately reported by telephone to the Primary Investigator, Alan. W. Partin M.D., Ph.D., (410) 614-4876.
&lt;/value&gt;!!&lt;Identifier&gt;57&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development and Evaluation of a Tumor Marker for Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The Biomarker Knowledge System Informatics Pilot Project goal will develop network interfaces among databases that contain information about existing clinical populations and biospecimens and data relating to those specimens that are important in biomarker assay validation.  This protocol comprises one of two that will comprise the Moffitt participation in the Biomarker Knowledge System Informatics Pilot Project.   THIS PROTOCOL (58) is the Sput-Epi Database.&lt;/value&gt;!!&lt;Identifier&gt;58&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;The Biomarker Knowledge System Informatics Pilot Project Supplement To The Biomarker Development Laboratory at Moffitt (Bedlam)&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;59&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;CLUE Studies: Evaluating Biomarkers of Carcinogenesis&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;60&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Clinical Validation of Molecular Signatures of Cervical Neoplasia&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;61&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Protocol for Comparing Promoter Hypermethylation Methods in NSCLC&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;62&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;National Ovarian Cancer Early Detection Program Blood and Genetics&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;64&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;New Biomarkers &amp; Dysplastic Respiratory Epithelium&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;65&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Hereditary Cancer Institute family study specimen bank&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;66&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Informatics Pilot Project&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Recent advances in high-throughput protein expression profiling of bodily fluids has generated great enthusiasm and hope for this approach as a potent diagnostic tool. At the center of these efforts is the application of SELDI-TOF-MS and artificial intelligence algorithms by the EDRN BDL site at Eastern
Virginia Medical School and the DMCC respectively. When the expression profiling process was applied to sera from individuals with prostate cancer (N=197), BPH (N=92) or from otherwise healthy donors (N=97) we achieved an overall misclassification rate of &amp;#060;10%. The sensitivity was 83% and the specificity was 100%
with an overall positive predictive value of 91.15%. This result is a significant improvement over PSA which presents as only 25% specificity and &amp;#062;90% sensitivity. Since this represents a noticeable improvement in current clinical approach we are proposing to embark upon a validation process. The described studies are
designed to address validation issues and include three phases. Phase 1; Synchronization of SELDI Output within the EDRN-Prostate-SELDI Investigational Collaboration (EPSIC); addressing portability (A) Synchronize SELDI instrumentation and robotic sample processing across the EPSIC using pooled serum(QC); (B) Establish the portability and reproducibility of the SELDI protein profiling approach within the EPSIC using normal and prostate cancer patient’s serum from a single site; (C) Establish robustness of the
approach toward geographic, sample collection and processing differences within EPSIC using case and
control serum from five different sites. Phase 2; Population Validation Establish geographic variability and robustness in a large cross-sectional study among different sample population. Phase 3; Clinical Validation;
validate the serum protein expression profiling coupled with a learning algorithm as a means for early detection of prostate cancer using longitudinal PCPT samples. We have assembled a cohesive multi-institutional team for completing these studies in a timely and efficient manner. The team consists of five EDRN laboratories,
DMCC and CBI and the proposed budget reflects the total involvement.&lt;/value&gt;!!&lt;Identifier&gt;67&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Body Fluids as a Source of Diagnostic Biomarkers: Prostate&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;68&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Body Fluids as a Source of Diagnostic Biomarkers: Breast&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Lymphoma specimens were collected and analyzed for the presence of SV40 sequences. The DMCC analyzed data for Adi Gazdar&lt;/value&gt;!!&lt;Identifier&gt;69&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Presence of simian virus 40 DNA sequences in human&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;70&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Expression based markers for breast cancer detection&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;71&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast tissue array&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;72&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Dev Lab At Moffitt Supplement&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;73&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detecting Breast Cancer Signatures in Body Fluids&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;75&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Research Depository of Normal and Neoplastic Human Tissues&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;76&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Body Fluids as a Source of Diagnostic Biomarkers&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;77&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Molecular Genetics of Urinary Bladder Carcinoma&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;79&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Identification of protein and genetic biomarkers of prostate cancer and risk factors for progression of disease&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;80&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;MMR protein expression in HNPCC&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;81&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Methylation tumor markers in HNPCC&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;82&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Mutational load distribution analysis (MLDA) in pancreatic cancer&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;BACKGROUND: No proven ovarian cancer (OC) screening strategy exists for women who are at increased risk for the disease.  A risk of ovarian cancer algorithm (ROCA) using serial CA125 values have previously shown greater positive predictive value (PPV) and sensitivity than a single CA125 in screening women at general population risk.  We hypothesized that using ROCA would yield a reasonable PPV for ovarian cancer screening in a cohort at increased risk. METHODS: Between 7/2001 and 9/2006, 25 sites (14 CGN, 3 ovarian SPOREs, 1 EDRN, 7 others) prospectively enrolled patients. Inclusion criteria included: among self, 1st degree and 2nd degree relatives in same lineage either (i) BRCA 1/2 mutation, or (ii) two of OC or early onset (age &amp;#060; or = 50) breast cancer (BC), or (iii) Ashkenazi ethnicity and 1 of OC or BC.  A previous diagnosis of OC excluded subjects. Subjects underwent CA125 every 3 months and the risk of having ovarian cancer based on the CA125 profile was recalculated after each test. ROCA referred subjects with risk &amp;#062; 1% to ultrasound (US) and risk &amp;#062; 10% additionally to a gynecologic oncologist. Objectives included PPV for study indicated surgery, sensitivity, and compliance. Sample size was chosen to observe 8 OC endpoints with a power of 80% to rule out PPV &amp;#060; or = 10% if the true PPV = 20%.&lt;/value&gt;!!&lt;Identifier&gt;83&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Ovarian Cancer Screening Pilot Trial In High Risk Women&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;84&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;HNPCC colon cancer-associated SELDI mass spectrometry protein profiles in serum&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;86&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Molecular Detection of Invasive Bladder Cancer by Urine Examination&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;87&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Establishment of a serum standard for use in high-throughput proteomic&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;89&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detecting breast cancer protein signatures in body fluid&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;90&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Protein profiling for detection of high risk breast cancer&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;91&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SELDI and LC-MS/MS discovery and profiling study of hepatocarcinomas&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;92&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Collaborative study on SELDI biomarker discovery and serum protein profiling of lung cancers&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;93&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SELDI Profiling of serum and urine from patients with urologic disease in support of bladder cancer studies&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;94&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomic Profiling of Serum and Other Body Fluids for the Early Detection of Colon Cancers&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;95&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Development Laboratory&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;96&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Identification of New Markers in Normal and Abnormal Pap Smears&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;97&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early detection of liver cancer and hepatitis&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;98&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development of FISH-based assay for early detection of high grade cervical dysplasia&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;99&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detection of cancer DNA markers in urine&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;101&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Ornithine decarboxylase (ODC) Polymorphism and Breast and Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;102&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Ductal  Lavage Fluid Specimen Bank&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;103&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Inflammation as a Potential Marker of Risk ad Progression for Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;104&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Assessment of Clinical Potential of Digital SNP Analysis&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;105&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Ecogenetic Study of Lung Cancer&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;106&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;pre-operative plevic mass study&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;ELIGIBILITY CRITERIA 

3.1.    Inclusion Criteria.
3.1.1.&amp;nbsp;&amp;nbsp;&amp;nbsp;Adults (&amp;#062; 18 years old)
3.1.2.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with active or suspected Barrett’s esophagus including:
a.&amp;nbsp;&amp;nbsp;&amp;nbsp;Intestinal metaplasia without dysplasia, long and short segments
b.&amp;nbsp;&amp;nbsp;&amp;nbsp;Intestinal metaplasia with low-grade dysplasia
c.&amp;nbsp;&amp;nbsp;&amp;nbsp;Intestinal metaplasia with high-grade dysplasia
d.&amp;nbsp;&amp;nbsp;&amp;nbsp;Adenocarcinoma of the esophagus, primary diagnosis.
3.1.3.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients without Barrett’s after esophagoscopy.
3.1.4.&amp;nbsp;&amp;nbsp;&amp;nbsp;Able to physically tolerate removal of 30 – 60 ml of blood
3.1.5.&amp;nbsp;&amp;nbsp;&amp;nbsp;Tolerate extra research related biopsies
3.1.6.&amp;nbsp;&amp;nbsp;&amp;nbsp;Willing to permit extra blood/biopsies at endoscopic procedure 
3.1.7.&amp;nbsp;&amp;nbsp;&amp;nbsp;Ability and willingness to complete questionnaires
3.1.8.&amp;nbsp;&amp;nbsp;&amp;nbsp;Willing to sign informed consent.

3.2    Exclusion Criteria.
3.2.1.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with active gastrointestinal bleeding.
3.2.2.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with serious infections requiring IV antibiotics.
3.2.3.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with coagulopathies or on anticoagulant treatment.
3.2.4.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with known HIV or chronic viral hepatitis.
3.2.5.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients on active chemotherapy or radiation treatment.
3.2.6.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients who have had an esophagectomy.
3.2.7.&amp;nbsp;&amp;nbsp;&amp;nbsp;Patients with an active malignancy diagnosed or treated within 5 years except for squamous cell carcinoma of the skin, basal cell carcinoma of the skin; Carcinoma in situ, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery and/or radiation therapy; Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery.
&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;107&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;GLNE 003: Preliminary Validation of Biomarkers Predictive of Barrett’s Esophagus Progression to Dysplasia and Adenocarcinoma&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See MSA protocol&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Goal 1: To determine sensitivity and specificity of microsatellite analysis (MSA) of urine sediment, using a panel of 15 microsatellite markers, in detecting bladder cancer in participants requiring cystoscopy.  This technique will be compared to the diagnostic standard of cystoscopy, as well as to urine cytology.
Goal 2: To determine the temporal performance characteristics of microsatellite analysis of urine sediment.
Goal 3: To determine which of the 15 individual markers or combination of markers that make up the MSA test are most predictive of the presence of bladder cancer.
&lt;/value&gt;!!&lt;Identifier&gt;108&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detection of Bladder CA by Microsatellite Analysis (MSA)&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;109&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SELDI Phase I:  Assay Validation-Prostate&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;110&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SELDI Validation Study Phase II&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;111&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Serum Markers for the Early Detection of Hepatocellular Carcinoma&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;112&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Detection of Serum Proteomic Patterns and SNPs in Breast Cancer: A Pilot Study&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;113&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development of paraffin-based expression profiles to predict minimal vs. substantial risk of disease progression using retrospective datasets&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, CD49a+ stromal and CD31+ endothelial was carried out to identify candidates: CD90, AGR2, BCMP11, CEACAM5, CRISP3. Quantitative protomics was applied to measure these proteins in urine samples.&lt;/value&gt;!!&lt;Identifier&gt;114&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers for Prostate and Bladder Cancer&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;REFERENCE SETS A and C:

5.1 Clinical setting: Diagnosis of lung cancer

5.2 Cases eligibility Set A:

- All lung cancers discovered on CXR or on CT

- Pathology: confirmation of malignancy, all histological groups, primary lung cancer
- &amp;#8805;50% Stage I (Stage 1A = T1, N0, M0 and Stage 1B = T2, N0, M0)

   - No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last    5 years

   - Blood collected prior to treatment (chemo/radiation)

5.3 Controls eligibility Set A
- High risk individuals as defined by &amp;#062;50 YO, &amp;#062; 30 PKYs of smoking (prevalence of cancer ~1% based on (3-7)) with a lung lesions on CXR or on CT suspicious for lung cancer but proven not to be cancer at 1 year follow up.  If at 1 year follow up participant has been diagnosed with a type of cancer other than lung then the participant will be considered an “other cancer” control.

- 75 patients with pathology proven primary cancers from other organ sites (25 breast, 25 colon, 25 prostate)

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

Cases and controls will be matched for prevalence according to age, sex, race, smoking status,    and PKY history of smoking

5.4 Sample sizes Set A
(1) Rapid single biomarker pre-validation:    87 cases and 50 controls, 25 other cancer controls
   (2) Panel of biomarkers pre-validation:   150 cases and 150 controls
(3) Phase II validation:         180 cases and 180 controls, 75 other cancer controls

5.5 Institution provider candidates Set A   
Pittsburgh
Vanderbilt
MDACC
UCLA
   UCHSC
   NYU
   JHU
 
REFERENCE SET B:

5.6 Clinical setting Set B
CT screening trial for the early detection of lung cancer

5.7 Cases eligib&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;115&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Lung&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;116&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Resource Network Exchange&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;117&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Polyp Prediction Study&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See BRSCW description&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The purpose of this study is to develop a standard reference set of specimens for use by investigators participating in the National Cancer Institutes Early Detection Research Network (EDRN) in defining false positive rates for new cancer biomarkers in women.&lt;/value&gt;!!&lt;Identifier&gt;118&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Reference Sets for Cancers in Women&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Phase II specimens from 160 ovarian cancer cases and 640 benign disease or general population controls were assembled from four Early Detection Research Network (EDRN) or Ovarian Cancer Specialized Program of Research Excellence (SPORE) sites and used to rank 51 biomarkers.  Top markers in phase II specimens included CA125, HE4, transthyretin, CA15.3, and CA72.4 with sensitivity at 95% specificity ranging from 0.73 to 0.40.&lt;/value&gt;!!&lt;Identifier&gt;119&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;120&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Prostate&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;3 Subject Selection
3.1 Eligibility Criteria
3.1.1 Cases (n=300 invasive cancer and 100 DCIS: Up to 100 LCIS and 100 Pagets may
be included but are not the targeted population) and Benign Disease Controls (n=100 benign
non-proliferative conditions and 100 benign proliferative conditions)
a. Female
b. At least 18 years of age
c. Mammographic finding or palpable breast mass
d. Undergoing initial diagnosis to determine if breast cancer is present
3.1.2 Normal Controls (n=100):
a. Female
b. At least 18 years of age
c. Undergoing routine mammographic screening (with or without clinical breast
exam)
d. BIRADS score less than or equal to 2
3.2 Exclusion Criteria
3.2.1 Cases and Benign Disease Controls
a. Already diagnosed by biopsy for current presentation of breast cancer or benign
disease
b. History of invasive breast or other cancers (except basal or squamous cell
carcinoma of the skin)
c. Recurrence of previous breast cancer
d. Pregnant or nursing
The consenting process and blood draw will be carried out before primary pathology results
are obtained. This may occur either before or after the diagnostic biopsy, but will be limited
to the same day that the biopsy is performed or up to 2 weeks prior to biopsy. There are two
reasons for this restriction: 1) It will ensure that the cancer (or benign) mass is present at the
time of blood sampling and 2) It will reduce potential biases that might result from subjects
knowing their diagnosis with certainty to be malignant or benign. No exclusion will be
made based upon age, race, extent of disease, drug usage, family history, prior biopsies, prior
benign diseases or prior DCIS.
3.2.2 Normal Controls
a. Current evidence of breast abnormality (prior benign disease or DCIS
acceptable)
b. History of invasive breast or other cancers (except basal or squamous cell
carcinoma of the skin)
c. Pregnant or nursing
d. BIRADS score greater than 2 or palpable mass
For the purpose of this study, we defin&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The primary objective of this study is to assemble a well-characterized set of blood specimens to
test biomarkers that, in conjunction with mammography, can detect and discriminate breast
cancer. These samples will be divided to provide “sets” of specimens that can be tested in a
number of different laboratories. Since tests will be performed on the same sets of samples, the
data will be directly comparable and decisions regarding which biomarker or set of biomarkers
have value in breast cancer detection can be made. These sets will reside at a National Cancer
Institute facility at Frederick, MD.&lt;/value&gt;!!&lt;Identifier&gt;121&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Breast&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;122&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Longitudinal Serum Biorepository&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;123&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Novel Surveillance Strategies For Hereditary Nonpolyposis Colon Cancer Family Members&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;124&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Molecular Basis of Barrett&amp;#39;s -Associated Carcinogenesis&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;126&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN-WHI Pre-Clinical Colon Ca Specimens&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;127&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Pre-Validation Set&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;129&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Spectral Markers for Early Detection of Colon Neoplasia&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;3.2 Inclusion Criteria
3.2.1 Cases
Cases will include patients with HCC. Tumor staging will be performed using the modified TNM for HCC
used by UNOS. Early stage HCC is determined by the most recent CT or MRI that has lesion(s) and
maximum diameter. UNOS stage I (a single lesion &amp;#060; 2 cm) or stage II (single lesion between 2-&amp;#060;5 cm or
2-3 lesions each &amp;#060; 3 cm), with no vascular invasion (portal vein thrombosis) or extrahepatic metastasis.
Eligibility criteria for cases are:
&amp;#149; Age &amp;#062; 18 years of age
&amp;#149; Diagnosis HCC based on one of the following:
&amp;#1048707; Histology (required if only one lesion &amp;#060; 2 cm is present) – Must have CT/MRI to calculate
stage
&amp;#1048707; Two imaging tests, with at least one (CT/MRI/Angiography) within the past 3 months or up to
2 weeks after consent showing evidence of arterial hypervascularization, and the other within
the past 6 months (US, CT, MRI/Angiography) indicating a mass in the liver.
&amp;#149; MELD &amp;#060; 15. If MELD &amp;#062;15, but INR is &amp;#060; 1.5, Total Bilirubin is &amp;#060; 1.7 and patient has a history of
intrinsic renal disease, then eligible.
&amp;#149; Lab results (other than AFP) must be within the past 90 days. AFP results are optional.
&amp;#149; Able and willing to provide written informed consent
The diagnostic criteria requiring two imaging tests in absence of a biopsy are based on an HCC Consensus
Conference (8). While it is preferable to use histologic confirmation of HCC to determine eligibility, it is
recognized that biopsies are not commonly done in patients with suspected HCC because of concerns of
complications; histology will only be required for patients with only one lesion present that is less than 2
cm.
3.2.2 Controls
Eligibility criteria for controls are:
&amp;#149; Age &amp;#062; 18 years of age
&amp;#149; Diagnosis of cirrhosis based on liver histology. In the absence of histology, cirrhosis would be
defined by an ultrasound or CT scan showing a cirrhotic-appearing liver with splenomegaly and
platelet count of &amp;#060; 120 mm-3.&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;134&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Liver&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;136&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Soluble  Mesothelin Related Peptide (SMRP) and Osteopontin (OPN) as Early Detection Markers for Malignant Mesothelioma (MM)&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;100 cases and 200 controls will be selected based on retrospective chart review of endoscopic
and pathology reports demonstrating BE, defined as salmon-colored mucosa in the tubular esophagus with intestinal metaplasia with goblet cells on biopsy. The endoscopic procedures were done as per routine clinical care at participating Consortia institutions. Cases are those BE patients who initially had either no or low grade
dysplasia, who eventually progressed to have either HGD or EAC (progressors). Controls will include patients with BE who have not progressed beyond low grade dysplasia (non-progressors).
&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus (&amp;quot;progressors&amp;quot;), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC (&amp;quot;non-progressors&amp;quot;). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful  application for a prospective study of markers identified in this case-control study.&lt;/value&gt;!!&lt;Identifier&gt;137&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Barrett&amp;#39;s Esophagus Methylation Profiles&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;138&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;139&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers in Familial Multiple Myeloma&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;3.1 Cases (Pancreatic Cancer)
Patients will be consented prior to surgery.
A. No prior history of any other malignancy except nonmelanoma skin cancers for ten years.
B. Must have undergone complete surgical resection of the tumor with curative intent including the
presence of negative margins and a pathologic staging of I or IIA.
C. Must have histological verification of a pancreatic adenocarcinoma
D. Must not have received preoperative chemoradiation (neoadjuvant) therapy due to our inability to
adequately stage these patients.
E. Able to give informed consent.
F. Blood sample must be obtained within the past 2 weeks prior to surgery/anesthesia according to
procedure described in Appendix D.
Post-Enrollment Criteria: Inclusion of the patient in the proposed validation set is dependent on the results
of the surgery. The patient must have undergone complete surgical resection of the tumor with curative
intent including the presence of negative margins and a pathologic staging of I or IIA. Samples from any
patients not meeting these criteria will be used in a discovery set.
3.2 Controls
Three different control groups are proposed for this reference set: chronic pancreatitis patients, acute
benign biliary obstruction patients and healthy controls. The cases and controls are required to have a
similar age distribution. Although we will attempt to keep the same number of cases and controls within
each site (1 to 3 ratio), age distribution does not have to be similar for cases and controls within each site.
An algorithm developed by Feng and colleagues will be used to recruit cases and controls across multicenters
to ensure that the cases and controls are frequency matched by age. Eligibility criteria for each of
Page 4 of 7
the controls groups are described below. Control specimens will not be collected until 10 post-operative
PC cases have been successfully enrolled in the study.&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;185&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set:  Pancreatic&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;190&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;This project will generate a highly valuable data resource and make it available to all EDRN ovarian cancer researchers.  The resource will include comprehensive proteomic (tandem mass spectrometry, MS/MS) data generated from plasma samples that have been collected between four months and four years prior to clinical detection of ovarian cancer.  These pre-clinical samples, provided from the Beta Carotene and Retinol Efficacy Trial (CARET) prospective study, will be interrogated using IPAS, the proteomic profiling method developed by the Hanash Laboratory and with the quantitative methods developed by the McIntosh laboratory.  In addition, we will combine these pre-clinical data with already completed IPAS interrogations of plasma collected at the time of ovarian cancer diagnosis.  Thus together we will provide information on both pre-clinical and clinical behavior of a large number of proteins.  Based on our preliminary work we are able to quantify over 500 plasma proteins in each of these experiments, many of which are putative ovarian cancer biomarkers, showing the platform is capable of providing useful information regarding biomarker candidates.&lt;/value&gt;!!&lt;Identifier&gt;191&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomic Data Resources for EDRN Ovary Cancer Researchers within the EDRN&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;192&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;193&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of [-2]proPSA for the Early Detection of Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;194&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Release of Set Aside Funds - microRNA Biomarkers for Renal Cell Carcinoma&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion Criteria

Patients must fulfill all of the following criteria to be eligible:
1.  Histologically confirmed adenocarcinoma of
    the prostate.
2.  Clinically localized prostate cancer: T1-2,
    NX or N0, MX or M0.
3.  No previous treatment for prostate cancer
   (including hormonal therapy, radiation 
    therapy, surgery, or chemotherapy).
4.  ECOG Performance Status 0 or 1.
5.  Patient has elected Active Surveillance as
    preferred management plan for prostate cancer.
6.  Patient consent has been obtained according
    to local Institutional Review Board for
    acquisition of research specimens. 
7.  Patient is accessible and compliant for
    follow-up.
8.  Prostate biopsy requirements:

    a. If diagnosis was within one year of
       baseline visit, participant must have at 
       least one biopsy with at least 10 cores.
    b. If diagnosis was more than 1 year prior to
       baseline visit, participant must have a
       minimum of 2 biopsies, one of which must
       be within 2 years prior to baseline visit.

Exclusion Criteria
Patients who fulfill any of the following criteria are not eligible:

1. Unwillingness or inability to undergo serial
   prostate biopsy.

2. History of other malignancies, except: 
   adequately treated non-melanoma skin cancer or
   adequately treated superficial bladder cancer
  (Ta) or other solid tumors curatively treated
   with no evidence of disease for &amp;#062; 5 years.&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;195&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Active Surveillance Study&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion – Male and female patients must be diagnosed with acute or chronic pancreatitis, biliary obstruction, pancreatic cancer, or other gastrointestinal malignancies. Attempts will be made to recruit minorities. 
Exclusion – Do not expect to enroll children since pancreatic adenocarcinoma is a disease of adults that typically occurs in the 5th, 6th and 7th decades of life.
&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;196&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Adult males (ages 18-999) with a diagnosis of prostate cancer &lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;199&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Pre-Validation of Multiplex Biomarker in Urine&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential cancer biomarkers, especially those encoding secreted or extracellular proteins. These proteins might be detected in urine. CD90/THY1 is one such candidate. A clinical test based on urinary CD90 would be useful in reducing the number of unnecessary biopsies done because of abnormal serum PSA and/or DRE finding. Elevated CD90 protein is found in tumor tissue and urine.&lt;/value&gt;!!&lt;Identifier&gt;201&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Eligible subjects will be patients who have been referred for cystoscopy to evaluate microhematuria, voiding dysfunction or others concerns.
A) Inclusion criteria include:
1. Patient who is schedule to undergo cystoscopy as indicated in the evaluation of a specific urological condition (eg hematuria or voiding dysfunction)
2. Patient who is willing and able to provide a voided urine specimen for the study.
3. Patient who has signed informed consent
a. allowing processing/evaluation of urine for biomarker evaluation including DNA studies
b. allowing access of the research staff to the patient&amp;#39;s medical record e.g. to determine if bladder cancer diagnosed at cystoscopy or thereafter
B. Exclusion criteria include:
1. Patient not willing to sign informed consent
2. Patient unable to provide a voided urine sample
3. Previously treated malignancy
4. Previous recontructive genitourinary surgery (for example prior prostatectomy in men or augmentation cystoplasty in women would confound urinary methylation marker analysis)
5. Previous pelvic irradiation
6. Previous intravesical pharmacotherapy (eg BCG or DMSO)
7. Presence of urinary infection
8. Indwelling urinary catheter or stent

A. Cases are subjects whose cystoscopry or related clinical testing (eg biopsy pathology or urine cytology) indicates presence of transitional cell carcinoma.
B. Controls are subjects who are not found to have urothelial cancer after cystoscopy, biopsy pathology or urine cystology.
C. Participating subjects found to have non-transitional cell carcinoma (eg squamous cell carcinoma or adenocarcinoma) will be evaluated separately for the cases and controls, eg methylation will be studied for descriptive purposes but excluded from case-controls comparison.
&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;226&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Methylation &amp; Proteomics-Based Detection of Bladder Cancer&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;229&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarker Discovery for Renal Cell Carcinoma Through Serum, Urine and Tissue Protein Profiles&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;230&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pre-Validation of Metabolomic Biomarkers of Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;231&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Biomarker Reference Lab: Pacific Northwest National Laboratory&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;232&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer - Supplemental Pre-Validation Protocol&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;233&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PTM Microarray: Request for Year 3 Set-Aside Funds&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;234&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Cancer Early Detection Stem Cell Biomarkers (CA117452 Set-Aside)&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;236&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;237&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;High-Throughput Evaluation of Breast Cancer Markers&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;238&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Year 2 Collaborative Project - UCSF and Battelle PNWD&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;239&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;240&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Molecular Progression of Methylation in Bladder Cancer&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;241&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Integrated Development of Novel Molecular Markers&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;242&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Early Detection of Breast Cancer Using Autoantibody Markers&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;243&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomic Approach for Diagnostic Applications in Head and Neck Cancer&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Ovarian Cancer (350)(Sensitivity Trial) : The disease group includes women having newly diagnosed ovarian cancer (pelvic mass). The study will be done using archived specimens if they meet the specimen collection protocol  The diagnosis of ovarian cancer is done according to clinical, surgical, histological and pathologic diagnosis. The major histology groups (serous [borderline and invasive], mucinous, endometrioid, clear cell, and undifferentiated) will be represented proportional to their incidences.  Preliminary communication with PLCO investigators indicates that the histological distribution seen in PLCO matches ours expected design.  Within each histology, we will oversample early-stage disease where possible, with a goal of one-half early stage and one-half late stage. Control Group (1000)(Specificity Trial) a) Normal: The healthy control group includes age-matched healthy individuals, that come into the clinic for a regular gynecologic examination, who do not have a diagnosis of any type of cancer, or who are not genetically predisposed to develop ovarian cancer.  This group is available from the PLCO and will represent the majority (80%) of the samples evaluated. Similar criteria will be used for samples collected from all the sites.  b) High-Ris (50 samples): degree of risk is determined by formal genetic evaluation and categorized as mild (only one affected first-degree relative or a personal history of breast cancer), moderate (&amp;#8805; 2 affected first degree relatives), or high (BRCA1 or BRCA2 mutation inherited from an affected relative). It is estimated that over 50% of women with BRCA1 mutations that develop ovarian cancer are less than age 50.  Women with a BRCA1 mutation have approximately a 30-40% risk of developing ovarian cancer by age 70. Also included in this group are women with non-gynecologic malignancies, gynecological malignancies other than ovarian, and benign gynecologic conditions(50samples). In addition we will include 50 samples from pati&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;244&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Phase II Validation of a New Panel of Biomarkers for Early Detection of Ovarian Cancer&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;245&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Light Scattering Spectroscopy for the Detection of Colorectal Neoplasia&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;246&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate-Specific Glycoproteins for Early Detection of Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;247&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Colon Cancer Specimen Reference Set Application: Jendoubi - Milagen (2006)&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;248&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Colon Cancer Specimen Reference Set Application: Kim - DiaDexus (2008)&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see description of colon cancer reference set&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;249&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Colon Cancer Specimen Reference Set Application: Disis - University of Washington (2008)&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See summary of Colon Reference Set&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;250&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Colon Cancer Specimen Reference Set Application: Getzenberg - Johns Hopkins (2008)&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;251&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Standard Specimen Reference Set: Colon&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;254&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;255&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Development and Clinical Validation of Biomarkers for Prostate Cancer&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;256&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;257&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prognostic Markers in Lynch Syndrome Colorectal Cancers&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;258&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;A Methylation Panel for Bladder Cancer&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;259&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;The Early Detection Research Network: Biomarker Reference Laboratories&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;267&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Cancer Specimen Reference Set Application (Rapid): Giannelli - Univ of Bari (2008)&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion
&amp;#149;   Males greater than or equal to age 18
&amp;#149;   Patient scheduled for prostate biopsy for any of the following reasons:
o   PSA &amp;#062;2.0 ng/ml
o   Elevated PSA velocity (&amp;#062;0.4 ng/ml/yr)
o   Lower PSA value with other risk factors for PCa (e.g.; family history)
o   Prior ASAP or HGPIN
o   Abnormal DRE
o   % free PSA &amp;#060;15%
&amp;#149;   Finasteride/dutasteride and other medications for BPH and ED are allowable but will be recorded 
Exclusion
&amp;#149;   History of PCa
&amp;#149;   Urine not collected post DRE prior to index prostate biopsy
o   Blood can be collected up to 1 month before urine
o   Urine can be collected up to 1 month before index biopsy
&amp;#149;   Index prostate biopsy with &amp;#060;10 cores and without extended template
&amp;#149;   Index prostate biopsy pathology report unavailable
&amp;#149;   Participating in an intervention trial for prostate disease
&amp;#149;   Prior surgical (open or endoscopic) or minimally invasive treatment (TUNA/TUMT) for BPH
&amp;#149;   Prior saturation biopsy defined as at least 30 cores
&amp;#149;   Prior prostate biopsy within 6 months
&amp;#149;   Prior PCA3 test performed for clinical purpose
&amp;#149;   Consented more than 3 months before index biopsy
&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;274&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PCA3 Validation Study and Urinary Reference Set&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See Lung Reference Set A&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;279&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung Cancer Specimen Reference Set A (Full) Application:  Hirschowitz - University of Kentucky (2009)&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See Lung Reference Set A&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;280&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung Cancer Specimen Reference Set A (Full) Application:  Goodglick/Diamandis (2009)&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;281&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Canary TMA&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Ever smokers: person who has smoked &amp;#062;100 cigarettes during lifetime; Never Smokers: person who has smoked less than 100 cigarettes during lifetime; Current Smokers: person currently smoking who has quit for &amp;#062; one year; former smokers: smoker who has quit smoking for &amp;#062; one year; long-term former smokers: smoker who has quit smoking for &amp;#062; 10 years;
light smokers: smoker with total exposure of &amp;#062; 10 years.&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;282&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Identification of biomarkers for lung cancer in never smokers&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see description of Cancer in Women Reference Set&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Examine kallikreins as ovarian cancer biomarkers and determine sensitivity and specificity of panel&lt;/value&gt;!!&lt;Identifier&gt;283&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Applicant:  Diamandis - Mt Sinai (2006)&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;At least a 10 core biopsy with blood collected prior and serum stored at -70C for up to six years prior to analysis.&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;284&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set Application: Chan/Beckman Coulter (2007)&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Sample Eligibility defined in DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;285&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Reference Set Application (Rapid): Block - Drexel Univ (2008)&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Refer to reference set description&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;286&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set Application:  Haab - Van Andel (2006)&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;287&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set Applicant: Diamandis - Mt Sinai (2006)&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW protocol&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;One KLK,(KLK6) ranked 6th among all tested biomarkers(approx.50)&lt;/value&gt;!!&lt;Identifier&gt;288&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Application: Lokshin - Univ of Pitts (2008)&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;289&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Application: Mathew - Meso Scale (2006)&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;290&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;MALDI Dilution Data: Randolph&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;291&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Applicant: Wilson - EIC Laboratories, Inc (2007)&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;292&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Rapid Reference Set: Getzenberg - Johns Hopkins (2006)&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see BRSCW description&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Over 40 marker assays are available to run on the samples. These include markers such as Osteopontin, Mesothelin, Periostin, Endoglin, intestinal Fatty Acid Binding Protein, and FAS-Ligand, some of which have been previously described in the literature. Other proprietary markers are derived from internal discovery efforts and from collaborator programs.&lt;/value&gt;!!&lt;Identifier&gt;305&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Applicant:  Buechler - Biosite Inc (2009)&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;311&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Reference Set Applicant (Rapid #1): Lubman - Univ of Michigan&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;borderline ovarian cancers were excluded
postmenopausal women only&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;The obvious appeal of a strategy for the early detection of ovarian cancer is based upon the tendency for the disease to present at advanced stages associated with poor survival.  If the diagnosis could be largely shifted to stages I or II associated with survival close to 90%, then the overall mortality for this disease could be dramatically altered without any advances in therapy.  While approaches to ovarian cancer screening might include pelvic examination or sonography, a vast amount of information exists on potential blood markers for the disease.  The precision of sensitivity and specificity estimates will be greater for larger versus smaller study populations; but the effect produced by differences in the populations studied cannot as easily be predicted. Most of the studies relied on phase II validation (i.e. case vs. control differences); but case groups may differ by disease stage and histology that may affect overall estimates of sensitivity.  Many studies have limited case specimens to those collected pre-operatively, but not all were explicit in this regard.  Few studies have used pre-diagnostic sera months or years before diagnosis, so-called Phase III studies.  Similarly, the nature of the control group will also affect specificity estimates.  Inclusion of surgical controls that have benign gynecological conditions such as fibroids, endometriosis, or benign ovarian tumors may elevate marker levels and lower specificity.  One strategy, besides combining markers, to improve the sensitivity and/or specificity would be to use marker history in the context of serial testing.  Elevated but declining marker levels would indicate a transient condition associated with marker production.  Elevated but stable levels might indicate chronic but benign conditions associated with marker production, while elevated and increasing levels are more likely indicative of cancer. Our hypothesis is that a panel of biomarkers will have better performance characteristics as a screening test for pre-clinical ovarian cancer than any single marker, and yield a longer lead time than CA125 alone.&lt;/value&gt;!!&lt;Identifier&gt;312&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;PLCO Ovarian Phase III Validation Study&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Inclusion criteria:
- benign breast pathologies, 
- all types of breast malignancy, 
- pre/peri/post-menopausal status, 
- familial/genetic predisposition

exclusion criteria:
-   Pregnancy, 
-   Breast-feeding, 
-   alcohol and drug abuse.

&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;314&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Cancer: subgroups specific blood-biomarkers for early / predictive diagnosis and personalized treatment&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see Prostate Reference Set description&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;315&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Specimen Ref Set Applicant: Isaacs-JHU-2010&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;316&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Hepatocellular carcinoma Early Detection Strategy study&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Cases eligibility:
- All lung cancers discovered on CXR or on CT

- Pathology: confirmation of malignancy, all histological groups, primary lung cancer
- &amp;#8805;50% Stage I (Stage 1A = T1, N0, M0 and Stage 1B = T2, N0, M0)

   - No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last    5 years

   - Blood collected prior to treatment (chemo/radiation)

Controls eligibility
- High risk individuals as defined by &amp;#062;50 YO, &amp;#062; 30 PKYs of smoking (prevalence of cancer ~1% based on (3-7)) with a lung lesions on CXR or on CT suspicious for lung cancer but proven not to be cancer at 1 year follow up.  If at 1 year follow up participant has been diagnosed with a type of cancer other than lung then the participant will be considered an “other cancer” control.

- 75 patients with pathology proven primary cancers from other organ sites (25 breast, 25 colon, 25 prostate) – Set C only 37 other cancers.

- No prior history of lung and other cancer (except for basal cell carcinoma of the skin) in the last 5 years

Cases and controls will be matched for prevalence according to age, sex, race, smoking status, and PKY history of smoking
&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;317&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung C Reference Set (Full): Rachel Ostroff - SomaLogics (2010)&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;To-date, through the efforts of Co-Investigator Dr. John Wei in the Department of Urology, the University of Michigan EDRN has procured serum, plasma and urine from &amp;#062;1000 men referred to Dr. Wei with an indication for prostate biopsy. Of these, only 37.5% exhibit malignant glands on one or more needle biopsies. This is perhaps not surprising, as the majority (70%) of men referred for needle biopsy exhibit pre-biopsy PSA values of &amp;#060;10ng/ml, which, as described above, are not diagnostic for PCa. Taken together, these studies show that low serum PSA and other recently developed biomarkers cannot reliably distinguish between PCa and BPH or indicate which patients should, or should not, undergo diagnostic needle biopsy. Therefore, it is desirable to develop
and validate suitable biomarkers that could be used alone or in conjunction with PSA to distinguish patients at high risk for PCa who should undergo diagnostic needle biopsy from those
at low risk who could benefit from watchful waiting. &lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;STUDY DESIGN
1. The need for pre-validation studies. Preliminary data from our laboratory demonstrates a potential utility for CXCL5 and CXCL12 as biomarkers to distinguish between patients at high-risk versus low-risk for harboring prostate malignancies. However, this pilot and feasibility study utilized a very small sample size of 51 patients, which limited the ability of this study to adequately assess certain technical aspects of the ELISA technique and statistical aspects of  we propose studies designed assess the robustness (Specific Aim 1) and predictive value (Specific Aim 2) of these markers in a larger study population.
2. ELISA Assays. Serum, plasma, or urine chemokine levels are assessed using 50 ul frozen specimen per sandwich ELISA in duplicate using the appropriate commercially-available capture antibodies, detection antibodies, and standard ELISA reagents (R&amp;D Systems), as we have described previously (15, 17, 18). Measures within each patient group are regarded as biological replicates and permit statistical comparisons between groups. For all ELISAs, a standard curve is generated with the provided standards and utilized to calculate the quantity of chemokine in the sample tested. These assays provide measures of protein concentration with excellent reproducibility, with replicate measures characterized by standard deviations from the mean on the order of &amp;#060;3%.
&lt;/value&gt;!!&lt;Identifier&gt;318&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Chemokine Prostate Cancer Biomarkers&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Sample Eligibility defined in DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;319&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Reference Set Application (Full): Block - Drexel Univ (2010)&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;5.2   Eligibility 
5.2.1    Inclusion Criteria
&amp;#149;   Adults 50-80 and undergoing a colonoscopy defined as:
o   First time screening or a surveillance procedure  
o   No complete colon exam (colonoscopy or CT colonography) within 3 years except as noted. (see section 5.4.1)  
&amp;#149;   Willing to sign informed consent 
&amp;#149;   Able to physically tolerate removal of up to 50 ml of blood
&amp;#149;   Willing to collect 2 stool samples 
&amp;#149;   Willing to collect 150 ml of urine

5.2.2   Exclusion Criteria
&amp;#149;   Inability to provide informed consent
&amp;#149;   History of Inflammatory Bowel Disease
&amp;#149;   Overt rectal bleeding within (including due to suspected hemorrhoids).
&amp;#149;   Positive guiaic-based occult blood or fecal immunochemical test (e.g. FOBT, FIT) in the past 12 months.
&amp;#149;   Undergone resection of the colon for any indication
&amp;#149;   Subjects with known HIV or chronic viral hepatitis (Hepatitis B and C)
&amp;#149;   Subjects with known or suspected HNPCC (Lynch Syndrome) or FAP
&amp;#149;   Any cancer  within 5 years of enrollment except any of the following: 
o   Squamous cell carcinoma of the skin or Basal cell carcinoma of the skin
o   Carcinoma in situ of the cervix, Stages Ia or Ib invasive squamous cell carcinoma of the cervix treated by surgery only.  (Excluded if had pelvic radiation) 
o   Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery
&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;320&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Biomarkers for the Early Detection of Colorectal Adenocarcinoma (GLNE 010)&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;321&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung Reference Set A (Full) Applicant: Takacs - Biosystems (2010)&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;322&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Reference Set Applicant (Rapid #2): Lubman - Univ of Michigan&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;see cancer in women reference set description&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;324&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Applicant: Morre - NOX Technologies Inc. (2009)&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;326&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;US-Turkey Cappadocia Mesothelioma Project&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;See DCP Protocol&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;327&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;LIver Reference Set Applicant (Rapid) Yamada - Wako (2011)&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;328&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;LIver Reference Set Applicant (Rapid) Beretta-FHCRC (2011)&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;329&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;LIver Reference Set Applicant (Rapid) Qu-Quest (2011)&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;330&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Early Detection Ovarian Cancer Biomarkers (Team Project)&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Identification of eligible subjects:
Each participating CVC will utilize a registry of women who have had breast surgery for benign breast disease at the CVC hospital/cancer center in the time period 1 January 1994 through 31 December 2004.  Cases of atypical ductal hyperplasia (ADH) that meet the inclusion-exclusion criteria will be given a unique EDRN-VSIMS number. 
Study Cohort Inclusion Criteria:
1.Diagnosis of BBD with atypia (ADH).
2.Formalin-fixed archival tissue (preferably excisional biopsy or core biopsy) sufficient for 2 or more tissue sections.
3.Adequate follow-up information to determine subsequent cancer status (IBC yes-no).
4.Clinical information sufficient to determine race, family history of breast cancer, mammography history and breast surgery history, and clinical management and outcome of patients developing IBC.
Study Cohort Exclusion Criteria:
1.Women age &amp;#060; 40 or &amp;#062; 70 at the time of first BBD breast biopsy.
2.Women with diagnosed concurrent invasive breast cancer, DCIS, invasive lobular carcinoma or lobular carcinoma in situ.
3.Women with insufficient clinical information to determine subsequent breast health history including mammography status and invasive breast carcinoma.
4.Women who had only FNA or in whom the pathology bloc contains insufficient material for at least two cut sections.
 
&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;331&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Benign Breast Disease Team Project&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;333&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Triple Negative Breast Cancer Team Project&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;334&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Reference Set Applicant (Full): Yamada - Wako (2011)&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Since several different studies are involved, multiple eligibility criteria exist.&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;335&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Affinity-based strategies to fast track development of colon cancer biomarkers&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;336&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Reference Set Applicant (Full): Lubman - Univ of Michigan (2011)&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;1. Ovarian serous disease (benign or malignant) with cyst for cyst fluid extraction, age &amp;#062; 21
2 &amp; 3. ovarian serous cancer tissue, or normal fallopian tube tissue, age &amp;#062; 21
&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;337&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Proteomic Genetic and Longitudinal Pathways to Ovarian Cancer Biomarkers&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;338&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers of Risk for Colorectal Neoplasia&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;341&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Lung A Reference Set (Full) Applicant:  Coverley-York (2011)&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;342&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Cystic Fluid Reference Set&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;343&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers for the Early Detection of Pancreatic Cancer&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;344&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Reference Set Applicant (Rapid #2) Beretta-FHCRC (2011)&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;All study participants must be 18 years of age or older, able to physically tolerate removal of 30 – 60 ml of blood and willing to sign informed consent.  
   The criteria to be a healthy control are 1) no prior history of any other malignancy except non-melanoma skin cancers for the past ten years, 2) no personal history of colonic polyps, ulcerative colitis or crohn’s disease, and 3)    Normal colonoscopy with excellent or good colonic preparation within 2 years. 
   Adenomatous polyps patients will be defined as a colorectal polyp meeting histological criteria for adenomatous polyp that does not meet criteria for an advanced adenoma.
   Advanced adenomatous polyps will be defined as adenoma with significant villous features (&amp;#062;25%), size of 1.0 cm or more, high-grade dysplasia, or early invasive cancer
   Stage A/B colorectal cancer patients will be defined as any T, N0, and M0.  The patient must not have started any form of cancer treatment at the time of sample collection.
   Stage C/D colorectal cancer patients will be defined any T, N &amp;#062; 1, and any M.  The patient must not have started any form of cancer treatment at the time of sample collection.
&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;
1   AIMS
We propose a GI Collaborative biomarker validation project with the goal of identifying those biomarkers developed by the GI collaborative that will predict the presence of advanced colorectal adenomas.  Biomarkers from the diverse colon focused and pancreatic focused BDLs of the GI Collaborative will assay their biomarkers on sets of identical reference set samples.  The GI Collaborative will also assess markers of tissue/serum-plasma and/or urine from other EDRN collaborative groups, i.e. urologic, breast, lung, in this reference set.  The most promising biomarkers that meet required adenoma detection bars will be assayed in a second, blinded test set of biosamples from a separate group of subjects before being considered for inclusion in large, cross sectional biomarker validation project for the early detection of both colorectal adenocarcinomas and advanced adenomas. 

Aim 1
To define preliminary sensitivity, specificity, and their variance of biomarkers for the detection of advanced adenomas in a standardized, open labeled training biosample reference set.

Aim 2
To select those biomarkers for the detection of advanced adenomas in the training set for additional validation in a standardized biosample reference test set using pre-set performance characteristics.

Aim 3
To verify sensitivity, specificity, and their variance of biomarkers for the detection of advanced adenomas in a standardized, blinded test biosample reference set.

Aim 4
To select biomarkers for the detection of advanced adenomas from the test set for inclusion in a large, cross sectional validation trial of biomarkers for the early detection of advanced adenomas.

2   BACKGROUND AND SIGNIFICANCE
2.1   Current State of the Art: Recommended Early Detection
   Colorectal adenocarcinoma remains the most common fatal cancer among non-smokers in the United States.  Its lifetime incidence is sufficiently high at 6%, or 1 in 18, to justify population screening.  It is encouraging that both colorectal cancer incidence and mortality have decreased in the past decade, developments attributed at least in part to more effective screening and surveillance (1). Wide scale screening using fecal occult blood tests results in up to a 30% reduction in colorectal adenocarcinoma (CRC) mortality, but at the expense of many colonoscopies in patients without neoplasia (2-5).  Colonoscopy, while examining the complete colon, requires a thorough bowel preparation and sedation, causes patient discomfort, has a significant cost and carries a small, but non-negligible risk of complications (6-11). Patient-friendly approaches are needed with the combined features of high accuracy for cancer, high grade dysplasia, and adenomas &amp;#062;1cm (advanced adenomas including any tubulovillous and villous adenomas) and broad acceptability to the general population, health care providers, and third party payers (12).
&lt;/value&gt;!!&lt;Identifier&gt;347&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Preliminary Validation of Biomarkers for the Detection of Colorectal Adenomas (Team Project #1)&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;All patients will have, at baseline, one or more non-advanced or advanced adenoma.  Because the number and histology of the baseline adenomas will influence the scheduling of subsequent colonoscopies, the number and histology of adenomas (and, potentially, their interaction) and the time to subsequent screen will be used as covariates in all modeling.  &lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Investigators in the colon section of EDRN have a mutual interest in developing markers that would identify individuals at increased risk for colon neoplasia. Identifying biomarkers of risk is a high priority, because markers would offer the promise of guiding or tailoring expensive interventions such as colonoscopy to the target population most likely to benefit.  The goal of this project is to evaluate biomarkers in normal colonic mucosa to determine their relationship to the occurrence of short- and long-term colorectal neoplasia. Candidate markers have been proposed by participating investigators based on promising preliminary data. The purpose of this team project is to evaluate these markers in a common, tissue-based reference set, under a uniform, structured protocol. 
All markers will be evaluated in a similar, stepwise fashion. Step 1: To assess the reproducibility and variability of marker expression within individuals, marker expression will be evaluated in duplicate samples from the same region of the colon and in 3 different sites around the colon, the rectum, left and right colon. Step 2: To characterize the inter-subject variability in marker expression by disease phenotype, differences in marker expression in normal colonic mucosa between subjects with and without adenomatous polyps will be compared. Step 3: To examine the relationship between marker expression and long-term adenoma recurrence, marker expression will be compared among subjects with baseline adenomas who have a recurrence of adenomatous polyps compared to those who do not recur. The markers to be tested include methylated genes, 15-PGDH mRNA, creatine kinase B, and proteomic markers in tissue lysates evaluated by antibody array and via liquid chromatography-multiple reaction monitoring mass spectrometry. 

These efforts can potentially identify markers that stratify or delineate individuals who may benefit from chemoprevention or require more intensified surveillance regimens. By enhancing the evidence supporting a field effect of cancer risk and by characterizing the molecular events involved, these markers could assist in the rational allocation of colonoscopy resources, a priority in colorectal cancer screening and surveillance. 
&lt;/value&gt;!!&lt;Identifier&gt;348&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers of Risk for Colorectal Neoplasia (Team Project #2)&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;349&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;BRSCW Applicant: Tuszynski - Temple University (2012)&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;350&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Ref Set Applicant:  Anu Mathew-Meso Scale 2012&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;351&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;DCIS Team Project&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;352&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Pancreatic Reference Set Applicant-Haab (2012)&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;353&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Prostate Upgrading Team Project&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;354&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Validation of Molecular Biomarkers for the Early Detection of Lung Cancer in the setting of Indeterminate Pulmonary Nodules (Lung Team Project #2)&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;355&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Breast Reference Set Applicant:- Zangar-Pacific NW Nat&amp;#39;l Laboratory&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;356&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Liver Reference Set  (Rapid) Norman (2012)&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Study Overview. We will examine DNA extracted from FFPE sections from approximately 200 different surgically resected primary pancreatic tumors from the UNMC Department of Pathology and
Microbiology. DNA will be purified from those sections and subjected to deep sequencing for the entire TP53 locus.
Expected Outcomes
We expect to find a difference in the p53 mutation status between tumor samples from patients that ultimately experienced tumor recurrence (more aggressive) compared to those that did not. Parallel studies to develop ICP will enable us to rapidly develop a low cost platform to extend these studies to larger patient populations for future validation studies.
Future Studies
The experiments proposed in this application represent a state-of-the-art approach to identify molecular markers that will help clinicians to ascertain the tumor recurrence risk for their pancreatic cancer patients who have undergone a Whipple procedure. If our initial studies support the hypothesis that p53 mutations are associated with early metastasis of pancreatic cancer, these studies would be extended to other cohorts of patient samples that are available at other major centers that see pancreatic cancer patients. Development of ICE COLD-PCR platforms to screen for these mutations will facilitate a reliable, rapid and low cost method for predicting tumor aggressiveness in these patients, which will be deployed in future studies should the hypothesis be supported.&lt;/value&gt;!!&lt;Identifier&gt;357&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Hollingsworth - Aggressive vs Indolent 2012&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Because lung cancer occurs in both males and females and members of all ethnic groups, clinical specimens
from both sexes and a variety of ethnic groups will be utilized in the proposed studies. Human clinical
specimens of normal, premalignant, and malignant lung tissue utilized in Aim 1 are available through the UCLA
Lung Cancer SPORE Tissue Repository. The specimen bank includes males, females, and members of
ethnically/racially diverse groups. Research in this proposal will utilize existing specimens in the tissue
repository, so it will not be necessary to recruit new subjects for the research in this proposal. The approximate
composition of the tissue repository is described in the Table 2.
African Americans 5
Hispanic/Latino 1
Asian Americans 5
Native Americans0
Pacific Islanders 0
White 29
Other 0
Total 40
&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;358&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Dubinett - Targeted Sequencing 2012&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;359&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Hollingsworth - Aggressive vs Indolent 2012&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;Create repository with DNA samples extracted from normal tissue, BE, BE+LGD, BE+HGD,
and EAC&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;360&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;William Grady&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;cases stratified by no recurrence within three years “indolent” and recurrent within three years “aggressive.”&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;361&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non- progressing cancers&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;The first enrolled 1,907 breast cancer patients diagnosed between 55-74 years of age from 2000-2008,
and the other enrolled 1,028 younger women 20-44 years of age diagnosed from 2004-2010. Details regarding
the methods of both studies have been published.21,22 For this pilot study we propose to limit eligible cases to
the 321 Group Health Cooperative (GHC, a large integrated health organization serving western Washington
state) patients who underwent mammographic screening and were diagnosed between 40-74 years of age (so
that it is restricted to women for whom screening mammography may be recommended) with stage I or II
breast cancer. The study is restricted to women with stage I or II disease in order to make the patients uniform
with respect to stage, and because an appreciable majority of screen detected tumors diagnosed among
women in this age range are early stage.&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;Distinguishing aggressive cancers from non-aggressive or non-progressing cancers is an issue of both clinical
and public health importance particularly for those cancers with an available screening test. With respect to
breast cancer, mammographic screening has been shown in randomized trials to reduce breast cancer
mortality, but given the limitations of its sensitivity and specificity some breast cancers are missed by
screening. These so called interval detected breast cancers diagnosed between regular screenings are known
to have a more aggressive clinical profile. In addition, of those cancers detected by mammography some are
indolent while others are more likely to recur despite treatment. The pilot study proposed herein is highly
responsive to the EDRN supplement titled “Biomarkers to Distinguish Aggressive Cancers from Nonaggressive
or Non-progressing Cancers” in that it addresses both of the research objectives related to these
issues outlined in the notice for this supplement:
Aim 1: To identify biomarkers in tumor tissue related to risk of interval detected vs. mammography
screen detected breast cancer focusing on early stage invasive disease. We will compare gene
expression profiles using the whole genome-cDNA-mediated Annealing, Selection, extension and Ligation
(DASL) assay of 50 screen detected cancers to those of 50 interval detected cancers. Through this approach
we will advance our understanding of the molecular characteristics of interval vs. screen detected breast
cancers and discover novel biomarkers that distinguish between them.
Aim 2: To identify biomarkers in tumor tissue related to risk of cancer recurrence among patients with
screen detected early stage invasive breast cancer. Using the DASL assay we will compare gene
expression profiles from screen detected early stage breast cancer that either recurred within five years or
never recurred within five years. These two groups of patients will be matched on multiple factors including
tumor stage and treatments received. Our goal with this comparison is to identify novel biomarkers that
discriminate between tumors that recur and are more aggressive compared to those that are less aggressive
and do not recur.
This project will evaluate well characterized tumor tissue specimens using a robust high dimensional laboratory
approach and generate preliminary data that will motivate a larger scale study of high translational relevance.&lt;/value&gt;!!&lt;Identifier&gt;362&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Biomarkers to Distinguish Aggressive Cancers from Non-aggressive or Non-progressing Cancer&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Eligibility_criteria&lt;/slot&gt;&lt;value&gt;this proposal will provide for comprehensive profiling of DNA methylation across the promoter
associated CpG islands of 20 matched pairs (40 samples) of colon cancer hepatic metastasis and matched colon cancer primary tumors.&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Protocol_Abstract&lt;/slot&gt;&lt;value&gt;&lt;/value&gt;!!&lt;Identifier&gt;363&lt;/Identifier&gt;&lt;slot&gt;Title&lt;/slot&gt;&lt;value&gt;Targeted Sequencing for Discovery and Validation of DNA Methylation Markers of Colon Cancer Metastasis&lt;/value&gt;</Protocol_or_StudyResult></Protocol_or_StudyResponse></soap:Body></soap:Envelope>